<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="132805">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01888978</url>
  </required_header>
  <id_info>
    <org_study_id>2011-384</org_study_id>
    <nct_id>NCT01888978</nct_id>
  </id_info>
  <brief_title>Molecularly Tailored Therapy for Pancreas Cancer</brief_title>
  <official_title>A Pilot Study of Molecularly Tailored Therapy for Patients With Metastatic Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Georgetown University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Georgetown University</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is for patients with metastatic pancreatic cancer (cancer that has spread to
      other parts of the body). The purpose of this study is to determine whether molecularly
      tailored therapy can improve the effectiveness of standard chemotherapy combinations for
      patients with metastatic pancreatic cancer. A series of special tests will be performed on a
      sample of tumor, and based on the results subjects will be assigned to one of seven
      chemotherapy treatments, with each being the combination of two standard chemotherapies.
      Each of these combinations has been safely used in patients with pancreatic or other types
      of cancer. The purpose of this study is to to determine the ability to personalize therapy
      in this manner, and to determine how many patients a larger study would need. A second
      purpose is not to determine if one doublet is better than another. Rather, this second
      purpose is to show that for all patients enrolled in this protocol who have been assigned a
      doublet based on their tumor's molecular analysis (molecular tailoring), treatment response
      will be better than would be expected compared to patients who have been treated in the past
      with no molecular tailoring.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Timing of biopsy and treatment</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>The number of days from study entry to biopsy to molecular results to first dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estimates for future trials</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>objective response rate, proportions of patients with each molecular profile, timing of biopsy and therapy results, usefulness of molecular profile results and adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>confirmed classification of stable disease, partial response, or complete response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time in days from study entry until progression or death</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Modified FOLFOX-6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxaliplatin 85 mg/m2 day 1 and 5-fluorouracil 400 mg/m2 day 1 and Leucovorin 400 mg/m2 day 1 and 5-fluorouracil 2400 mg/m2 over 46 hours on day 1-3 of every 14 day cycle All drugs will be administered until disease progression or unacceptable toxicity are observed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ox-Tax</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel 65 mg/m2 and Oxaliplatin 100 mg/m2 on day 1 every 3 weeks All drugs will be administered until disease progression or unacceptable toxicity are observed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FOLFIRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Irinotecan 180 mg/m2 on day 1 and 5-FU 400 mg/m2 on day 1 and Leucovorin 400 mg/m2 day 1 and 5-FU 2400 mg/m2 over 46 hours, days 1-3 as a continuous infusion All drugs will be administered until disease progression or unacceptable toxicity are observed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tax-Iri</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 weeks on, 1 week off of Docetaxel 35 mg/m2/week and Irinotecan 50 mg/m2/week Both administered on day 1 of each week of treatment All drugs will be administered until disease progression or unacceptable toxicity are observed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gem-Ox</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcitabine: 1000 mg/m2 over 100 minutes on Day 1 Oxaliplatin: 100 mg/m2 over 120 minutes on Day 2 of every 14 day cycle All drugs will be administered until disease progression or unacceptable toxicity are observed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gem-5FU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcitabine: 1000 mg/m2 over 30 minutes 5-FU 2000/m6 as a 24 hour infusion on days 1, 8, and 15 of every 28 day cycle All drugs will be administered until disease progression or unacceptable toxicity are observed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gem-Tax</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcitabine 1000 mg/m2 over 30 minutes and Docetaxel 35 mg/m2 over 60 minutes on days 1, 8, and 15 of every 28 day cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gem-OX</intervention_name>
    <arm_group_label>Gem-Ox</arm_group_label>
    <other_name>Gemcitabine</other_name>
    <other_name>Gemzar</other_name>
    <other_name>Oxaliplatin</other_name>
    <other_name>Eloxatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gem-5FU</intervention_name>
    <arm_group_label>Gem-5FU</arm_group_label>
    <other_name>Gemcitabine</other_name>
    <other_name>Gemzar</other_name>
    <other_name>5-FU</other_name>
    <other_name>5-fluorouracil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gem-Tax</intervention_name>
    <arm_group_label>Gem-Tax</arm_group_label>
    <other_name>Gemcitabine</other_name>
    <other_name>Gemzar</other_name>
    <other_name>Docetael</other_name>
    <other_name>taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Modified FOLFOX-6</intervention_name>
    <arm_group_label>Modified FOLFOX-6</arm_group_label>
    <other_name>Oxaliplatin</other_name>
    <other_name>Eloxatin</other_name>
    <other_name>5-FU</other_name>
    <other_name>5-Fluorourcil</other_name>
    <other_name>Leucovorin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ox-Tax</intervention_name>
    <arm_group_label>Ox-Tax</arm_group_label>
    <other_name>Docetaxel</other_name>
    <other_name>Taxotere</other_name>
    <other_name>Oxalipaltin</other_name>
    <other_name>Eloxatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFIRI</intervention_name>
    <arm_group_label>FOLFIRI</arm_group_label>
    <other_name>Irinotecan</other_name>
    <other_name>CPT-11</other_name>
    <other_name>5-FU</other_name>
    <other_name>5-Fluorouracil</other_name>
    <other_name>Leucovorin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tax-Iri</intervention_name>
    <arm_group_label>Tax-Iri</arm_group_label>
    <other_name>Docetaxel</other_name>
    <other_name>Taxotere</other_name>
    <other_name>Irinotecan</other_name>
    <other_name>CPT-11</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven pancreatic adenocarcinoma with measurable disease

          -  Biopsy accessible tumor deposits

          -  ECOG performance status 0-2

          -  Age &gt;/= 18 years

          -  Subjects with no brain metastases or history of previously treated brain metastases

          -  Adequate hepatic, renal, and bone marrow function

          -  Partial thromboplastin time must be &lt;/= 1.5 x upper normal limit of institution's
             normal range and INR &lt; 1.5

          -  Life expectancy &gt; 12 weeks

          -  Women of childbearing potential must have a negative seum pregnancy test within 14
             days prior to initiation of treatment

          -  Subject is capable of understanding and complying with parameters as outlines in the
             protocol and able to sign and date the consents

        Exclusion Criteria:

          -  CNS metastases which do not meet criteria outlines in inclusion criteria

          -  Active severe infection or known chronic infection with HIV or hepatitis B virus

          -  Cardiovascular disease

          -  Life threatening visceral disease or other severe concurrent disease

          -  Women who are pregnant, breastfeeding, or women of childbearing potential not using
             dual forms of effective contraception

          -  Anticipated patient survival under 3 months

          -  Patients receiving any other investigational agents

          -  History of allergic reactions attributed to compounds of similar chemical or
             biological composition to gemcitabine, oxaliplatin, 5-FU, docetaxel or irinotecan

          -  Uncontrolled intercurrent illness
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Pishvaian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Georgetown University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lisa Ley, MSN</last_name>
    <phone>202-687-6653</phone>
    <email>leyl@georgetown.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karen Vogel, RN</last_name>
    <phone>202-687-6974</phone>
    <email>kd252@georgetown.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Georgetown University- Lombardi Comprehensive Cancer Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Ley, MSN</last_name>
      <phone>202-687-6653</phone>
      <email>leyl@georgetown.edu</email>
    </contact>
    <contact_backup>
      <last_name>Karen Vogel, RN</last_name>
      <phone>202-687-6974</phone>
      <email>kd252@georgetown.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Pishvaian, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MedStar Montgomery Medical Center</name>
      <address>
        <city>Olney</city>
        <state>Maryland</state>
        <zip>20832</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Anderson, RN</last_name>
      <phone>301-774-8989</phone>
    </contact>
    <investigator>
      <last_name>Michael Pishvaian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 12, 2014</lastchanged_date>
  <firstreceived_date>June 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pancreas</keyword>
  <keyword>cancer</keyword>
  <keyword>metastatic</keyword>
  <keyword>chemotherapy</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
